Cell and Gene Therapy CRO Market Size, Share & Trends Analysis Report, By Type of Cell Therapy (CAR-NK, CAR-T, TCR-T, and Others), By Type of Genetic Modification (Ex vivo and In vivo), By Stage of Development (Discovery, Preclinical, and Clinical)), By Therapeutic Area, By End-user, By Region, Forecasts, 2024-2031

Cell and Gene Therapy CRO Market Size was valued at USD 1.46 Bn in 2023 and is predicted to reach USD 2.43 Bn by 2031 at a 6.7% CAGR during the forecast period for 2024-2031.

Cell and gene therapy involves manipulating a patient's cells to introduce, remove, or alter specific genes in order to correct genetic problems. By getting to the bottom of hereditary disorders like cystic fibrosis and cancer, this treatment approach has promise. Clinical trials have revealed promising outcomes, and it holds potential for individualized therapy. Correction of genetic defects or modification of gene expression to improve cardiac and vascular function is the main goal of gene therapy in the treatment of coronary artery disease.

One approach to cell and gene therapy that makes use of viral vectors is the delivery of therapeutic genes to cells in the cardiovascular system. Increased awareness of gene therapy and substantial investments in research and development are driving forces behind the cell and gene therapy CRO market's rapid expansion. Cell and gene therapy is anticipated to have a significant impact on the cancer treatment industry due to several variables, including rising cancer rates, ethical acceptance of the treatment, and more support from the government. The rising incidence of long-term diseases, including cancer, rare genetic disorders affecting a wide range of uncommon diseases, and others, is a major force propelling the gene therapy market forward.

However, the market growth is hampered by the high-cost criteria for the safety and health of the call and gene therapy market. The product's inability to prevent fog in environments with dramatic temperature fluctuations or high call and gene therapy due to complex manufacturing, long clinical trials, strict regulatory requirements, and gene therapy incurs high R&D expenses. These monetary roadblocks cause businesses trouble because they reduce their investment potential, which in turn reduces development and market accessibility. If gene therapy is to advance and become more accessible to patients, the prohibitive expense must be addressed. Due to the COVID-19 pandemic, which has affected the worldwide market and forced the closure of numerous factories in an effort to protect their personnel from contracting the virus, the expansion of the industry may be hindered.

Competitive Landscape

Some of the Major Key Players in the Cell and Gene Therapy CRO Market are

• Altasciences
• Allucent
• CMIC
• Labcorp
• Linical
• Medpace
• PPD
• Precision for Medicine
• QPS
• Syneos Health
• CMED
• ICON
• Pharmalex
• Novotech

Market Segmentation:

Cell and gene therapy CRO market is segmented based on type of cell therapy, stage of development, type of genetic modification, therapeutic area, and end-users. Based on type, the market is segmented into Ex vivo and In vivo. Based on the stage of development, the market is segmented into discovery, preclinical, and clinical. Based on therapeutic area, the market is segmented into blood disorders, cardiovascular disorders, dermatological disorders, immunological disorders, infectious diseases, metabolic disorders, musculoskeletal disorders, neurological disorders, oncological disorders, rare diseases, and other disorders. On the basis of type of cell therapy, market segmented into CAR-NK, CAR-T, TCR-T, and others. Type of genetic modification includes ex-vivo and in-vivo. By end-users, the market is segmented into industry players and non-industry players.

Cardiovascular Disorders Segment is Dominate the Market

The cardiovascular disorders segment of the cell and gene therapy CRO market is expected to hold a major global market share in 2023. The need for pharmaceutical compounds to treat arterial and cardiovascular ailments is rising globally. With more and more people suffering from heart conditions, the pharmaceutical chemicals market is seeing growth in cardiovascular applications.

Clinical Segment to Witness Growth at a Rapid Rate

Cell and gene therapies are groundbreaking treatments, but require rigorous testing before reaching patients. Due to this, the clinical segment dominates the CRO market in this field. CROs, or Contract Research Organizations, handle clinical trials for pharmaceutical and biotech companies. These trials involve multiple stages with increasing numbers of participants to assess safety and effectiveness. CROs with clinical expertise understand the strict regulations for cell and gene therapies and guide their clients through the approval process. With the focus on safety and navigating regulations, the clinical segment is crucial. Even though the gene therapy segment itself is projected to grow, the clinical segment will likely remain on top as companies develop and test these innovative therapies.

North American Cell and Gene Therapy CRO Market Holds a Significant Revenue Share

The North American cell and gene therapy CRO market is expected to register the highest market share in revenue in the near future. It can be attributed to the prevalence of chronic diseases, high and rising healthcare expenditure, an advanced healthcare infrastructure, available reimbursements, and the presence of major market players. In addition, Asia Pacific is projected to grow rapidly in the global cell and gene therapy in market due to the huge amount of registered clinical trials linked to the treatments. The significant focus on government funding and reforms is another factor expected to contribute to expanding the region's chimeric antigen gene therapy market in the coming years.

Recent Developments:

• In January 2024, ICON plc announced that Chief Financial Officer Brendan Brennan would resign in the final period of this year to pursue an adventure within the CRO field. To facilitate a seamless transfer to the new Chief Financial Officer, Brendan will continue in his current position and join the firm. A hunt for ICON's next chief financial officer has begun.

• In March 2024, Novotech announced that the Commission for Drugs for Humans of the European Medicines Agency (EMA) has recommended that Fabhalta (iptacopan) be approved for marketing to treat adulthood with nocturnal paroxysms of hemoglobin (PNH) and hemolytic anemia.

Cell and Gene Therapy CRO Market Report Scope